Comparing the costs and benefits of the use of an mRNA HR-HPR assay to a DNA HR-HPV assay in the proposed cervical screening programme in France

Cervical cancer is the fourth most common cancer in women aged 15 to 44 years in France. With the implementation of cytology-based cervical screening, cervical cancer incidence and mortality have decreased over time, however, cervical cancer remains a concern. As cervical cancer is primarily caused by persistent infection with high-risk human papillomaviruses (HR-HPV), guidelines for a national cervical screening programme were recently updated to include the use of HR-HPV assays in cervical screening in France.

As the type of HR-HPV test used can impact costs and resources, Aquarius developed a decision tree model simulating the French cervical screening algorithms using French cost and population data and data from the Danish Horizon study to compare the use of the Aptima mRNA HR-HPV assay to a DNA HR-HPV assay.

Continue reading